We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+31.73%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$422M
AUM Growth
+$153M
Cap. Flow
+$112M
Cap. Flow %
26.56%
Top 10 Hldgs %
59.67%
Holding
84
New
36
Increased
11
Reduced
13
Closed
17

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$9.63M
2
TSRO
TESARO, Inc.
TSRO
+$5.7M
3
VIVE
VIVEVE MED INC
VIVE
+$5.55M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$5.36M
5
ZGNX
Zogenix, Inc.
ZGNX
+$4.43M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$21.3M
2
AKBA icon
Akebia Therapeutics
AKBA
+$7.28M
3
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$5.35M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$4.98M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$4.47M

Sector Composition

Rank Sector Weight
1 Healthcare 60.69%
2 Technology 1.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.62B
$50.6M 12%
+730,000
New +$49M
IWM icon
2
PUT
iShares Russell 2000 ETF
IWM
$81.5B
$39.9M 9.45%
290,000
+220,000
+314% +$30.1M
VCYT icon
3
Veracyte
VCYT
$3.58B
$28.3M 6.71%
3,083,559
-429,602
-12% -$3.52M
ASMB icon
4
Assembly Biosciences
ASMB
$503M
$28M 6.65%
91,667
+10,284
+13% +$2.52M
IOVA icon
5
Iovance Biotherapeutics
IOVA
$1.93B
$25.4M 6.03%
3,415,044
-394,900
-10% -$2.89M
IRIX icon
6
IRIDEX
IRIX
$14.4M
$20.1M 4.76%
1,691,865
+137,719
+9% +$1.94M
ACAD icon
7
Acadia Pharmaceuticals
ACAD
$4.39B
$19.7M 4.67%
572,756
+272,756
+91% +$9.63M
ASND icon
8
Ascendis Pharma A/S
ASND
$16B
$15.4M 3.65%
550,000
-25,309
-4% -$640K
PDSB icon
9
PDS Biotechnology
PDSB
$40M
$12.3M 2.92%
67,576
+15,563
+30% +$3.08M
NDRM
10
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$11.9M 2.83%
450,000
-215,944
-32% -$5.35M
WBMD
11
CALL
DELISTED
WebMD Health Corp.
WBMD
$10M 2.37%
+190,000
New +$9.7M
NBRV
12
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$8.13M 1.93%
2,711
-115
-4% -$280K
BCRX icon
13
BioCryst Pharmaceuticals
BCRX
$2.24B
$7.73M 1.83%
920,310
+770,310
+514% +$5.36M
ACAD icon
14
CALL
Acadia Pharmaceuticals
ACAD
$4.39B
$7.22M 1.71%
+210,000
New +$7.41M
VIVE
15
DELISTED
VIVEVE MED INC
VIVE
$7.22M 1.71%
+1,140
New +$5.55M
CASM
16
DELISTED
CAS Medical Systems, Inc.
CASM
$6.41M 1.52%
4,422,500
+242,662
+6% +$369K
CEMI
17
DELISTED
Chembio diagnostics, Inc.
CEMI
$6.37M 1.51%
1,202,144
+51,219
+4% +$298K
OXFD
18
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$5.98M 1.42%
386,100
-84,734
-18% -$1.21M
ACRS icon
19
Aclaris Therapeutics
ACRS
$772M
$5.96M 1.41%
200,000
-172,753
-46% -$4.98M
TSRO
20
DELISTED
TESARO, Inc.
TSRO
$5.38M 1.28%
+35,000
New +$5.7M
MRVL icon
21
Marvell Technology
MRVL
$174B
$5.34M 1.27%
350,000
-150,000
-30% -$2.31M
RARX
22
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$5.28M 1.25%
247,956
-129,953
-34% -$2.48M
DBVT
23
DBV Technologies
DBVT
$804M
$5.27M 1.25%
14,969
+5,779
+63% +$2.03M
ASMB icon
24
CALL
Assembly Biosciences
ASMB
$503M
$5.1M 1.21%
16,667
+15,834
+1,901% +$3.88M
JNJ icon
25
PUT
Johnson & Johnson
JNJ
$613B
$4.98M 1.18%
+40,000
New +$4.78M
1
2 3 4

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q1 2017 Portfolio in Review

As of Q1 2017, Acuta Capital Partners held 84 positions worth $422M, up 57% from $269M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Acuta Capital Partners deployed $112M of net new capital in Q1 2017, opening 36 new positions and adding to 11 existing holdings. Its largest new stake was TESARO, Inc.: 35,000 shares worth $5.38M.

By sector, the portfolio is most concentrated in Healthcare at 61% of assets, down from 77% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Immunomedics Inc, an estimated $21.3M trimmed.

  • Acuta Capital Partners's largest Q1 2017 buy was TESARO, Inc.: 35,000 shares worth $5.38M.
  • Acuta Capital Partners added most to Acadia Pharmaceuticals in Q1 2017, an estimated $9.63M increase.
  • Acuta Capital Partners's biggest Q1 2017 reduction was Immunomedics Inc, cutting an estimated $21.3M.
  • Acuta Capital Partners fully exited Akebia Therapeutics in Q1 2017, selling an estimated $7.28M.
  • Acuta Capital Partners's ten largest holdings make up 60% of its $422M portfolio in Q1 2017.
  • Acuta Capital Partners opened 36 new positions and closed 17 in Q1 2017.
  • Acuta Capital Partners's portfolio value rose 57% quarter-over-quarter to $422M.

Based on Acuta Capital Partners's 13F filing for Q1 2017, filed 15 May 2017.